Oncopeptides will continue to focus on further developing and expanding the company’s project portfolio. Available financial resources and the reported results shall therefore be reinvested in the business to finance the company’s long-term strategy. The board’s intention is not to propose a dividend to shareholders before the company is able to generate long-term sustainable profitability.
Any future dividends and the size thereof will be determined on the basis of the company’s long-term growth, earnings trend and capital requirements, taking into account the current objectives and strategies adopted. Dividends shall, in so far as dividends are proposed, be well-balanced with respect to the company’s targets, scope and risk.